Esperion Therapeutics, Inc.
ESPR
$3.78
$0.123.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.98% | 26.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.98% | 26.76% | |||
| Cost of Revenue | 54.89% | -18.85% | |||
| Gross Profit | -31.57% | 122.99% | |||
| SG&A Expenses | 5.92% | -8.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.19% | -13.55% | |||
| Operating Income | -240.37% | 132.11% | |||
| Income Before Tax | -146.23% | 68.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -146.23% | 68.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -146.23% | 68.55% | |||
| EBIT | -240.37% | 132.11% | |||
| EBITDA | -239.47% | 132.27% | |||
| EPS Basic | -142.39% | 68.78% | |||
| Normalized Basic EPS | -142.18% | 68.74% | |||
| EPS Diluted | -142.39% | 69.33% | |||
| Normalized Diluted EPS | -142.18% | 68.74% | |||
| Average Basic Shares Outstanding | 1.61% | 0.72% | |||
| Average Diluted Shares Outstanding | 1.61% | 0.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||